Lower risks for anxiety disorders, substance use disorders, cognitive deficits seen for those undergoing metabolic and bariatric surgery ...

(Nasdaq:MODD) has shared new data highlighting the use of its insulin pump technology to deliver GLP-1 therapeutics.

The New England Journal of Medicine (NEJM) published results from Novo Nordisk's phase 3 REDEFINE 1 trial evaluating the efficacy and safety of investigational CagriSema plus lifestyle interventions ...

Hims & Hers delivered record Q1 results and expanded into Europe with the Zava acquisition. Click here to see why HIMS stock is a Hold.

Patients who took a GLP-1 drug fared better than those in a control group at keeping their blood glucose levels in a healthy ...

In a rodent model of type 2 diabetes (T2D), icovamenib in combination with low-dose semaglutide promoted enhanced glycemic control and b ...

The Phase 2 randomized, double-blind, placebo-controlled clinical trial was conducted by Vincentage to investigate the ...

In a Phase 2a clinical trial, the GLP-1 RA bofanglutide injection demonstrated a favorable safety and tolerability profile after 23 weeks of once weekly treatment in patients with type 2 diabetes ...

Compounded vs non-compounded GLP-1 RA drug products are associated with an increased risk for adverse events such as nausea and diarrhea.

A new study published in the journal of Liver International showed that persons with type 2 diabetes had a threefold ...

Discover how GLP-1 drugs are driving demand for new supplements. Insights from Vitafoods Europe 2025 reveal how the industry ...